Research programme: CNS therapeutics - Eli Lilly/NeuroSearchAlternative Names: CNS therapeutics - Eli Lilly/NsDiscovery
Latest Information Update: 04 Dec 2013
At a glance
- Originator NeuroSearch
- Mechanism of Action Ion channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued CNS disorders